GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » 3-Year EPS without NRI Growth Rate

Lumos Pharma (FRA:4NX1) 3-Year EPS without NRI Growth Rate : -65.00% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma 3-Year EPS without NRI Growth Rate?

Lumos Pharma's EPS without NRI for the three months ended in Mar. 2024 was €0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -65.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Lumos Pharma was 64.50% per year. The lowest was -67.10% per year. And the median was -2.90% per year.


Competitive Comparison of Lumos Pharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Lumos Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's 3-Year EPS without NRI Growth Rate falls into.



Lumos Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Lumos Pharma  (FRA:4NX1) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Lumos Pharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (FRA:4NX1) Business Description

Industry
Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines